The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

M. Ozcelik; H. Odabas; O. Ercelep; S. Yuksel; A. G. Mert; D. Aydin; H. Surmeli; D. Isik; S. Isik; A. Oyman; Basak Oven Ustaalioglu; Mehmet Aliustaoglu; Mahmut Gumus

Ayuda

The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

M. Ozcelik ^[2] ; H. Odabas ^[2] ; O. Ercelep ^[2] ; S. Yuksel ^[2] ; A. G. Mert ^[2] ; D. Aydin ^[2] ; H. Surmeli ^[2] ; D. Isik ^[2] ; S. Isik ^[2] ; A. Oyman ^[2] ; B. B. Oven Ustaalioglu ^[3] ; M. Aliustaoglu ^[2] ; M. Gumus ^[1]
1. [1] Bezmiâlem Vakıf Üniversitesi
  
  Bezmiâlem Vakıf Üniversitesi
  
  Turquía
2. [2] Kartal Dr. Lutfi Kirdar Education and Research Hospital, Turquía
3. [3] Haydarpasa Numune Education and Research Hospital, Turquía
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 6 (June 2016), 2016, págs. 617-624
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Aim The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to evaluate the activity of bevacizumab plus capecitabine combination in elderly mCRC patients who were not suitable for chemotherapy with irinotecan and oxaliplatin-containing regimens.
  
  Materials and methods Seventy years and older patients with metastatic colorectal carcinoma were included in this retrospective study. Bevacizumab was administered at a dose of 7.5 mg/kg on day 1 as an intravenous (IV) infusion over 30–90 min every 21 days, and capecitabine was prescribed at 1000 mg/m2 twice daily on days 1–14 of the same 21-day schedule.
  
  Results Eighty-two consecutive patients (47 men, 35 women) were included in the study. The mean age was 75.5 (SD 3.9, range 70–87). Half of the patients were older than 75 years. There were 55 patients (67.1 %) with a good Eastern Cooperative Oncology Group (ECOG) performance status (PS: 0–1) and the remaining 27 patients (32.9 %) had a poor ECOG performance status (PS: 2). With a median follow-up period of 18.5 months, the median progression-free survival (PFS) was 10 months (95 % CI, 7.8–12.1) and the median OS was 25 months (95 % CI, 18.6–31.3). The main toxicities recorded were non-hematological. Thirty-one patients (37 %) experienced grade 3/4 adverse events, the most common being hand–foot syndrome (9.8 %). No fatal toxicity resulting from this regimen was recorded.
  
  Conclusions Considering the toxicity profile and survival outcomes, the combination regimen of capecitabine and bevacizumab is a potentially feasible treatment option in elderly mCRC patients.